Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas

Information

  • Patent Grant
  • 7329670
  • Patent Number
    7,329,670
  • Date Filed
    Monday, December 27, 1999
    24 years ago
  • Date Issued
    Tuesday, February 12, 2008
    16 years ago
Abstract
The compounds are aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B where A is the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. The compounds inhibit raf kinase and are useful in the treatment of RAF kinase mediated diseases.
Description
FIELD OF THE INVENTION

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.


BACKGROUND OF THE INVENTION

The p21ras oncogene is a major contributor to the development and progression of human solid cancers and is mutated in 30% of all human cancers (Bolton et al. Ann. Rep. Med. Chem. 1994, 29, 165-74; Bos. Cancer Res. 1989, 49, 4682-9). In its normal, unmutated form, the ras protein is a key element of the signal transduction cascade directed by growth factor receptors in almost all tissues (Avruch et al. Trends Biochem. Sci. 1994, 19, 279-83). Biochemically, ras is a guanine nucleotide binding protein, and cycling between a GTP-bound activated and a GDP-bound resting form is strictly controlled by ras' endogenous GTPase activity and other regulatory proteins. In the ras mutants in cancer cells, the endogenous GTPase activity is alleviated and, therefore, the protein delivers constitutive growth signals to downstream effectors such as the enzyme raf kinase. This leads to the cancerous growth of the cells which carry these mutants (Magnuson et al. Semin. Cancer Biol. 1994, 5, 247-53). It has been shown that inhibiting the effect of active ras by inhibiting the raf kinase signaling pathway by administration of deactivating antibodies to raf kinase or by co-expression of dominant negative raf kinase or dominant negative MEK, the substrate of raf kinase, leads to the reversion of transformed cells to the normal growth phenotype (see: Daum et al. Trends Biochem. Sci. 1994, 19, 474-80; Fridman et al. J. Biol. Chem. 1994, 269, 30105-8. Kolch et al. (Nature 1991, 349, 426-28) have further indicated that inhibition of raf expression by antisense RNA blocks cell proliferation in membrane-associated oncogenes. Similarly, inhibition of raf kinase (by antisense oligodeoxynucleotides) has been correlated in vitro and in vivo with inhibition of the growth of a variety of human tumor types (Monia et al., Nat. Med. 1996, 2, 668-75).


SUMMARY OF THE INVENTION

The present invention provides compounds which are inhibitors of the enzyme raf kinase. Since the enzyme is a downstream effector of p21ras, the instant inhibitors are useful in pharmaceutical compositions for human or veterinary use where inhibition of the raf kinase pathway is indicated, e.g., in the treatment of tumors and/or cancerous cell growth mediated by raf kinase. In particular, the compounds are useful in the treatment of human or animal, e.g., murine cancer, since the progression of these cancers is dependent upon the ras protein signal transduction cascade and therefore susceptible to treatment by interruption of the cascade, i.e., by inhibiting raf kinase. Accordingly, the compounds of the invention are useful in treating solid cancers, such as, for example, carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon, myeloid disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).


The present invention, therefore, provides compounds generally described as aryl ureas, including both aryl and heteroaryl analogues, which inhibit the raf pathway. The invention also provides a method for treating a raf mediated disease state in humans or mammals. Thus, the invention is directed to compounds and methods for the treatment of cancerous cell growth mediated by raf kinase comprising administering a compound of formula I




embedded image



wherein B is generally an unsubstituted or substituted, up to tricyclic, aryl or heteroaryl moiety with up 30 carbon atoms with at least one 5 or 6 member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur. A is a heteroaryl moiety discussed in more detail below.


The aryl and heteroaryl moiety of B may contain separate cyclic structures and can include a combination of aryl, heteroaryl and cycloalkyl structures. The substituents for these aryl and heteroaryl moieties can vary widely and include halogen, hydrogen, hydrosulfide, cyano, nitro, amines and various carbon-based moieties, including those which contain one or more of sulfur, nitrogen, oxygen and/or halogen and are discussed more particularly below.


Suitable aryl and heteroaryl moieties for B of formula I include, but are not limited to aromatic ring structures containing 4-30 carbon atoms and 1-3 rings, at least one of which is a 5-6 member aromatic ring. One or more of these rings may have 1-4 carbon atoms replaced by oxygen, nitrogen and/or sulfur atoms.


Examples of suitable aromatic ring structures include phenyl, pyridinyl, naphthyl, pyrimidinyl, benzothiozolyl, quinoline, isoquinoline, phthalimidinyl and combinations thereof, such as diphenyl ether (phenyloxyphenyl), diphenyl thioether (phenylthiophenyl), diphenyl amine (phenylaminophenyl), phenylpyridinyl ether (pyridinyloxyphenyl), pyridinylmethylphenyl, phenylpyyridinyl thioether (pyridinylthiophenyl), phenylbenzothiazolyl ether (benzothiazolyloxyphenyl), phenylbenzothiazolyl thioether (benzothiazolylthiophenyl), phenylpyrimidinyl ether, phenylquinoline thioether, phenylnaphthyl ether, pyridinylnapthyl ether, pyridinylnaphthyl thioether, and phthalimidylmethylphenyl.


Examples of suitable heteroaryl groups include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms. Each ring typically has 3-7 atoms.


For example, B can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,3,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 4-, 5-, 6- or 7-benz-1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, or 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, or additionally optionally substituted phenyl, 2- or 3-thienyl, 1,3,4-thiadiazolyl, 3-pyrryl, 3-pyrazolyl, 2-thiazolyl or 5-thiazolyl, etc. For example, B can be 4-methyl-phenyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrryl, 1-methyl-3-pyrazolyl, 5-methyl-2-thiazolyl or 5-methyl-1,2,4-thiadiazol-2-yl.


Suitable alkyl groups and alkyl portions of groups, e.g., alkoxy, etc., throughout include methyl, ethyl, propyl, butyl, etc., including all straight-chain and branched isomers such as isopropyl, isobutyl, sec-butyl, tert-butyl, etc.


Suitable aryl groups include, for example, phenyl and 1- and 2-naphthyl.


Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclohexyl, etc. The term “cycloalkyl”, as used herein, refers to cyclic structures with or without alkyl substituents such that, for example, “C4 cycloalkyl” includes methyl substituted cyclopropyl groups as well as cyclobutyl groups. The term “cycloalkyl” also includes saturated heterocycles.


Suitable halogens include F, Cl, Br, and/or I, from one to persubstitution (i.e., all H atoms on the group are replaced by halogen atom), being possible, mixed substitution of halogen atom types also being possible on a given moiety.


As indicated above, these ring systems can be unsubstituted or substituted by substituents such as halogen up to per-halosubstitution. Other suitable substituents for the moieties of B include alkyl, alkoxy, carboxy, cycloalkyl, aryl, heteroaryl, cyano, hydroxy and amine. These other substituents, generally referred to as X and X′ herein, include —N, —CO2R5, —C(O)NR5R5′, —C(O)R5, —NO2, —OR5, —SR5, —NR5R5′, —NR5C(O)OR5′, —NR5C(O)R5′, C1-C10 alkyl, C2-10-alkenyl, C1-10-alkoxy, C3-C10 cycloalkyl, C6-C14 aryl, C7-C24 alkaryl, C3-C13 heteroaryl, C4-C23 alkheteroaryl, substituted C1-C10 alkyl, substituted C2-10-alkenyl, substituted C2-10-alkoxy, substituted C3-C10 cycloalkyl, substituted C4-C23 alkheteroaryl and —M—L1.


Where a substituent, X or X′, is a substituted group, it is preferably substituted by one or more substituents independently selected from the group consisting of —CN, —CO2R5, —C(O)R5, —C(O)NR5R5′, —OR5, —SR5, —NR5R5′, —NO2, —NR5C(O)R5′, —NR5C(O)OR5′ and halogen up to per-halo substitution.


The moieties R5 and R5′ are preferably independently selected from H, C1-C10 alkyl, C2-10-alkenyl, C3-C10 cycloalkyl, C6-C14 aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4-C23 alkheteroaryl, up to per-halosubstituted C1-C10 alkyl, up to per-halosubstituted C2-10-alkenyl up to per-halosubstituted C3-C10 cycloalkyl, up to per-halosubstituted C6-C14 aryl and up to per-halosubstituted C3-C13 heteroaryl.


The bridging group M is preferably —O—, —S—, —N(R5)—, —(CH2)—m, —C(O)—, —CH(OH)—, —NR5C(O)NR5R5′—, —NR5C(O)—, —C(O)NR5—, —(CH2)mO—, —(CH2)—m, —(CH2)mN(R5)—, —O(CH2)m—, —CHXa, —CXa2—, —S—(CH2)m— and —N(R5)(CH2)m—, where m=1-3, and Xa is halogen.


The moiety L is preferably a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Zn1, wherein n1 is 0 to 3.


Each Z substituent is preferably independently selected from the group consisting of —CN, —CO2R5, —C(O)NR5R5′, —C(O)—NR5, —NO2, —OR5, —SR5, —NR5R5′, —NR5C(O)OR5′, —C(O)R5, —NR5C(O)R5′, C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14 aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4-C23 alkheteroaryl, substituted C1-C10 alkyl, substituted C3-C10 cycloalkyl, substituted C7-C24 alkaryl and substituted C4-C23 alkheteroaryl. If Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of —CN, —CO2R5, —C(O)NR5R5′, —OR5, —SR5, —NO2, —NR5R5′,


—NR5C(O)R5′ and —NR5C(O)OR5′.


The aryl and heteroaryl moieties of B of Formula I are preferably selected from the group consisting of




embedded image



which are unsubstituted or substituted by halogen, up to per-halosubstitution. X is as defined above and n=0-3.


The aryl and heteroaryl moieties of B are more preferably of the formula:


wherein M is selected from the group consisting of —O—, —S—, —CH2—, —SCH2—, —CH2S—, —CH(OH)—, —C(O)—, —CXa2, —CXaH—, —CH2O— and —OCH2— and Xa is halogen.




embedded image


L is a six member aromatic structure containing 0-2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution and L1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution. X, Z, n and n1 are as defined above, and s=0 or 1.


In preferred embodiments, L is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution and L1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo substitution, or —M—L1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halo substitution. Z and X are preferably independently selected from the group consisting of —R6, —OR6 and —NHR7, wherein R6 is hydrogen, C1-C10-alkyl or C3-C10-cycloalkyl and R7 is preferably selected from the group consisting of hydrogen, C3-C10-alkyl, C3-C6-cycloalkyl and C6-C10-aryl, wherein R6 and R7 can be substituted by halogen or up to per-halosubstitution.


The heteroaryl moiety A of formula I is preferably selected from the group consisting of




embedded image



wherein R1 is preferably selected from the group consisting of C3-C10 alkyl, C3-C10 cycloalkyl, up to per-halosubstituted C1-C10 alkyl and up to per-halosubstituted C3-C10 cycloalkyl and R2 is C6-C14 aryl, C3-C14 heteroaryl, substituted C6-C14 aryl or substituted C3-C14 heteroaryl.


Where R2 is a substituted group, the substituents are preferably independently selected from the group consisting of halogen, up to per-halosubstitution, and Vn, where n=0-3.


Each V is preferably independently selected from the group consisting of —CN, —OC(O)NR5R5′, —CO2R5, —C(O)NR5R5′, —OR5, —SR5, —NR5R5′, —C(O)R5, —NR5C(O)OR5′; —SO2R5, —SOR5, —NR5C(O)R5′, —NO2, C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14 aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4-C24 alkheteroaryl, substituted C1-C10 alkyl, substituted C3-C10 cycloalkyl, substituted C6-C14 aryl, substituted C3-C13 heteroaryl, substituted C7-C24 alkaryl and substituted C4-C24 alkheteroaryl.


If V is a substituted group, it is preferably substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, —CN, —CO2R5, —C(O)R5, —C(O)NR5R5, —NR5R5′, —OR5, —SR5, —NR5C(O)R5′, —NR5C(O)OR5′ and —NO2.


The substituents R5 and R5′ are preferably each independently selected form the group consisting of H, C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14 aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4-C23 alkheteroaryl, up to per-halosubstituted C1-C10 alkyl, up to per-halosubstituted C3-C10 cycloalkyl, up to per-halosubstituted C6-C14 aryl and up to per-halosubstituted C3-C13 heteroaryl.


R2 is preferably substituted or unsubstituted phenyl or pyridinyl, where the substituents for R2 are selected from the group consisting of halogen, up to per-halosubstitution and Vn1, wherein n=0-3. Each V1 is preferably independently selected from the group consisting of substituted and unsubstituted C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, —NO2, —NH2, —C(O)—C1-6 alkyl, —C(O)N—(C1-6 alkyl)2, —C(O)NH—C1-6 alkyl, —O—C1-6 alkyl, —NHC(O)H, —NHC(O)OH, —N(C1-6 alkyl)C(O)—C1-6 alkyl, —N—(C1-6 alkyl)C(O)—C1-6 alkyl, —NHC(O)—C1-6 alkyl, —OC(O)NH—C6-14, —NHC(O)O—C1-6 alkyl, —S(O)—C1-6 alkyl and —SO2—C1-6 alkyl. Where V1 is a substituted group, it is preferably substituted by one or more halogen, up to per-halosubstitution.


Most preferably, R2 is selected from substituted and unsubstituted phenyl or pyridinyl groups, where the substituents are halogen and Wn (n=0-3).


W is preferably selected from the group consisting of —NO2, —C1-3 alkyl, —NH(O)CH3, —CF3, —OCH3, —F, —Cl, —NH2, —OC(O)NH— up to per-halo substituted phenyl, —SO2CH3, pyridinyl, phenyl, up to per-halosubstituted phenyl and C1-C6 alkyl substituted phenyl.


The invention also relates the compounds within the scope of general formula I described above. These more particularly include pyrazolyl ureas of the formula




embedded image



furyl ureas of the formula




embedded image



and thienyl ureas of the formula




embedded image



wherein R1, R2 and B are as defined above.


The present invention is also directed to pharmaceutically acceptable salts of formula I. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid. In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li+ Na+ or K+), alkaline earth cations (e.g., Mg+2, Ca+2 or Ba+2), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, pyridine, N,N-dimethylaminopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).


The compounds of Formula I may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative methods are presented to aid one of skill in the art in synthesizing the inhibitors, with more detailed examples being presented in the experimental section describing the working examples.


General Preparative Methods


Heterocyclic amines may be synthesized utilizing known methodology (Katritzky, et al. Comprehensive Heterocyclic Chemistry; Permagon Press: Oxford, UK (1984). March. Advanced Organic Chemistry, 3rd Ed.; John Wiley: New York (1985)). For example, as shown in Scheme 1,5-aminopyrazoles substituted at the N−1 position with either aryl or heteroaryl moieties may be synthesized by the reaction of an α-cyanoketone (2) with the appropriate aryl- or heteroaryl hydrazine (3, R2=aryl or heteroaryl). Cyanoketone 2, in turn, is available from the reaction of acetamidate ion with an appropriate acyl derivative, such as an ester, an acid halide, or an acid anhydride. In cases where the R2 moiety offers suitable anion stabilization, 2-aryl- and 2-heteroarylfurans may be synthesized from a Mitsunobu reaction of cyanoketone 2 with alcohol 5, followed by base catalyzed cyclization of enol ether 6 to give furylamine 7.




embedded image



Scheme I. Selected General Methods for Heterocyclic Amine Synthesis


Substituted anilines may be generated using standard methods (March. Advanced Organic Chemistry, 3rd Ed.; John Wiley: New York (1985). Larock. Comprehensive Organic Transformations; VCH Publishers: New York (1989)). As shown in Scheme II, aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H2 or a hydride transfer agent, such as formate, cyclohexadiene, or a borohydride (Rylander. Hydrogenation Methods; Academic Press: London, UK (1985)). Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlH4 (Seyden-Penne. Reductions by the Alumino- and Borohydrides in Organic Synthesis; VCH Publishers: New York (1991)), or using a zero valent metal, such as Fe, Sn or Ca, often in acidic media. Many methods exist for the synthesis of nitroaryls (March. Advanced Organic Chemistry, 3rd Ed.; John Wiley: New York (1985). Larock. Comprehensive Organic Transformations; VCH Publishers: New York (1989)).




embedded image



Scheme II Reduction of Nitroaryls to Aryl Amines


Nitroaryls are commonly formed by electrophilic aromatic nitration using HNO3, or an alternative NO2+ source. Nitro aryls may be further elaborated prior to reduction. Thus, nitroaryls substituted with




embedded image



potential leaving groups (eg. F, Cl, Br, etc.) may undergo substitution reactions on treatment with nucleophiles, such as thiolate (exemplified in Scheme III) or phenoxide. Nitroaryls may also undergo Ullman-type coupling reactions (Scheme III).




embedded image



Scheme III Selected Nucleophilic Aromatic Substitution Using Nitroaryls


As shown in Scheme IV, urea formation may involve reaction of a heteroaryl isocyanate (12) with an aryl amine (11). The heteroaryl isocyanate may be synthesized from a heteroaryl amine by treatment with phosgene or a phosgene equivalent, such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl) carbonate (triphosgene), or N,N′-carbonyldiimidazole (CDI). The isocyanate may also be derived from a heterocyclic carboxylic acid derivative, such as an ester, an acid halide or an anhydride by a Curtius-type rearrangement. Thus, reaction of acid derivative 16 with an azide source, followed by rearrangement affords the isocyanate. The corresponding carboxylic acid (17) may also be subjected to Curtius-type rearrangements using diphenylphosphoryl azide (DPPA) or a similar reagent. A urea may also be generated from the reaction of an aryl isocyanate (15) with a heterocyclic amine.




embedded image



Scheme IV Selected Methods of Urea Formation (Het=heterocycle)


Finally, ureas may be further manipulated using methods familiar to those skilled in the art. For example, 2-aryl and 2-heteroarylthienyl ureas are available from the corresponding 2-halothienyl urea through transition metal mediated cross coupling reactions (exemplified with 2-bromothiophene 25, Scheme V). Thus, reaction of nitrile 20 with an α-thioacetate ester gives 5-substituted-3-amino-2-thiophenecarboxylate 21 (Ishizaki et al. JP 6025221). Decarboxylation of ester 21 may be achieved by protection of the amine, for example as the tert-butoxy (BOC) carbamate (22), followed by saponification and treatment with acid. When BOC protection is used, decarboxylation may be accompanied by deprotection giving the substituted 3-thiopheneammonium salt 23. Alternatively, ammonium salt 23 may be directly generated through saponification of ester 21 followed by treatment with acid. Following urea formation as described above, bromination affords penultimate halothiophene 25. Palladium mediated cross coupling of thiophene 25 with an appropriate tributyl- or trimethyltin (R2=aryl or heteroaryl) then affords the desired 2-aryl- or 2-heteroarylthienyl urea.




embedded image


The invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.


The compounds may be administered orally, topically, parenterally, by inhalation or sprays vaginally, sublingually, or rectally in dosage unit formulations. The term ‘administration by injection’ includes intravenous, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques. Dermal administration may include topical application or transdermal administration. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.


Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.


Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.


Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example, lecithin, or condensation products or an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.


Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.


The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.


Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.


Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.


The compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.


Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien: “Transdermal Controlled Systemic Medications”: Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 3 Mar. 1994). For example, a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.


Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane. Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.


Suitable penetration enhancing materials for transdermal delivery system are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C8-C18 fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C8-C18 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl isobutyl tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C8-C18 fatty alcohols, saturated or unsaturated C8-C18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.


Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.


For all regimens of use disclosed herein for compounds of Formula I, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily rectal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily topical dosage regime will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg. The daily inhalation dosage regime will preferably be from 0.01 to 10 mg/Kg of total body weight.


It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be appreciated by one skilled in the art that the specific dose level for any given patient will depend upon a variety of factors, including, the activity of the specific compound administered, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy. It will be further appreciated by one skilled in the art that the optimal course of treatment, i.e., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.


It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the condition undergoing therapy.


The entire disclosure of all applications, patents and publications cited above and below are hereby incorporated by reference, including provisional application Ser. No. 60/135,502, filed on Dec. 22, 1997 as Ser. No. 08/996,181 converted on Dec. 22, 1998.


The compounds are producible from known compounds (or from starting materials which, in turn, are producible from known compounds), e.g., through the general preparative methods shown below. The activity of a given compound to inhibit raf kinase can be routinely assayed, e.g., according to procedures disclosed below. The following examples are for illustrative purposes only and are not intended, nor should they be construde to limit the invention in any way.







EXAMPLES

All reactions were performed in flame-dried or oven-dried glassware under a positive pressure of dry argon or dry nitrogen, and were stirred magnetically unless otherwise indicated. Sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa. Unless otherwise stated, the term ‘concentration under reduced pressure’ refers to use of a Buchi rotary evaporator at approximately 15 mmHg.


All temperatures are reported uncorrected in degrees Celsius (° C.). Unless otherwise indicated, all parts and percentages are by weight.


Commercial grade reagents and solvents were used without further purification. Thin-layer chromatography (TLC) was performed on Whatman® pre-coated glass-backed silica gel 60A F-254 250 μm plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, (d) immersion of the plate in a cerium sulfate solution followed by heating, and/or (e) immersion of the plate in an acidic ethanol solution of 2,4-dinitrophenylhydrazine followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science® silica gel.


Melting points (mp) were determined using a Thomas-Hoover melting point apparatus or a Mettler FP66 automated melting point apparatus and are uncorrected. Proton (1H) nuclear magnetic resonance (NMR) spectra were measured with a General Electric GN-Omega 300 (300 MHz) spectrometer with either Me4Si (0.00) or residual protonated solvent (CHCl3 7.26; MeOH 3.30; DMSO 2.49) as standard. Carbon (13C) NMR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDCl3 77.0; MeOD-d3; 49.0; DMSO-d6 39.5) as standard. Low resolution mass spectra (MS) and high resolution mass spectra (HRMS) were either obtained as electron impact (EI) mass spectra or as fast atom bombardment (FAB) mass spectra. Electron impact mass spectra (EI-MS) were obtained with a Hewlett Packard 5989A mass spectrometer equipped with a Vacumetrics Desorption Chemical Ionization Probe for sample introduction. The ion source was maintained at 250° C. Electron impact ionization was performed with electron energy of 70 eV and a trap current of 300 μA. Liquid-cesium secondary ion mass spectra (FAB-MS), an updated version of fast atom bombardment were obtained using a Kratos Concept 1-H spectrometer. Chemical ionization mass spectra (CI-MS) were obtained using a Hewlett Packard MS-Engine (5989A) with methane as the reagent gas (1×10−4 torr to 2.5×10−4 torr). The direct insertion desorption chemical ionization (DCI) probe (Vacumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held at 10 amps until all traces of the sample disappeared (˜1-2 min). Spectra were scanned from 50-800 amu at 2 sec per scan. HPLC-electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a C-18 column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-800 amu using a variable ion time according to the number of ions in the source. Gas chromatography-ion selective mass spectra (GC-MS) were obtained with a Hewlett Packard 5890 gas chromatograph equipped with an HP-1 methyl silicone column (0.33 M coating; 25 m×0.2 mm) and a Hewlett Packard 5971 Mass Selective Detector (ionization energy 70 eV).


Elemental analyses were conducted by Robertson Microlit Labs, Madison N.J. All ureas displayed NMR spectra, LRMS and either elemental analysis or HRMS consistant with assigned structures.












List of Abbreviations and Acronyms:


















AcOH
acetic acid



anh
anhydrous



BOC
tert-butoxycarbonyl



conc
concentrated



dec
decomposition



DMPU
1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone



DMF
N,N-dimethylformamide



DMSO
dimethylsulfoxide



DPPA
diphenylphosphoryl azide



EtOAc
ethyl acetate



EtOH
ethanol (100%)



Et2O
diethyl ether



Et3N
triethylamine



m-CPBA
3-chloroperoxybenzoic acid



MeOH
methanol



pet. ether
petroleum ether (boiling range 30-60° C.)



THF
tetrahydrofuran



TFA
trifluoroacetic acid



Tf
trifluoromethanesulfonyl











A. General Methods for Synthesis of Heterocyclic Amines


A1. General Procedure for the Preparation of N′-Aryl-5-aminopyrazoles



embedded image


N′-(4-Methoxyphenyl)-5-amino-3-tert-butylpyrazole: A mixture of 4-methoxyphenylhydrazine hydrochloride (3.5 g), 4,4-dimethyl-3-oxopentanenitrile (2.5 g), EtOH (30 mL), and AcOH (1 mL) was heated at the reflux temperature for 3 h, cooled to room temp., and poured into a mixture of EtO (100 mL) and a 10% Na2CO3 solution (100 mL). The organic layer was washed with a saturated NaCl solution, dried (MgSO4) and concentrated under reduced pressure. The solid residue was washed with pentane to afford the desired pyrazole as a pale brown solid. (4.25 g): 1H-NMR (DMSO-d6) δ 1.18 (s, 9H); 3.78 (s, 3H); 5.02 (br s, 2H); 5.34 (s, 1H); 6.99 (d, J=8 Hz, 2H); 7.42 (d, J=8 Hz, 2H).


A2. General Method for the Mitsunobu-Based Synthesis of 2-Aryl-3-aminofurans



embedded image


Step 1. 4,4-Dimethyl-3-(4-pyridinylmethoxy)-2-pentenenitrile: A solution of triphenylphosphine (2.93 g, 11.2 mmol) in anh THF (50 mL) was treated with diethyl azodicarboxylate (1.95 g, 11.2 mmol) and 4-pyridinylmethanol (1.22 g, 11.2 mmol), then stirred for 15 min. The resulting white slurry was treated with 4,4-dimethyl-3-oxopentanenitrile (1.00 g, 7.99 mmol), then stirred for 15 min. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (30% EtOAc/70% hexane) to give the desired nitrile as a yellow solid (1.83 g, 76%): TLC (20% EtOAc/80% hexane) Rf 0.13; 1H-NMR (CDCl3) δ1.13 (s, 9H), 4.60 (s, 1H), 5.51 (s, 2H), 7.27 (d, J=5.88 Hz, 2H), 8.60 (d, J6.25 Hz, 2H); 13C-NMR (CDCl3) δ 27.9 (3C), 38.2, 67.5, 70.8, 117.6, 121.2 (2C), 144.5, 149.9 (2C), 180.7; CI-MS m/z (rel abundance) 217 ((M+H)+, 100%).




embedded image


Step 2. 3-Amino-2-(4-pyridinyl)-5-tert-butylfuran: A solution of 4,4-dimethyl-3-(4-pyridinylmethoxy)-2-pentenenitrile (1.55 g, 7.14 mmol) in anh DMSO (75 mL) was treated with potassium tert-butoxide (0.88 g, 7.86 mmol) and stirred at room temp for 10 min. The resulting mixture was treated with EtOAc (300 mL), then sequentially washed with water (2×200 mL) and a saturated NaCl solution (100 mL). Combined aqueous phases were back-extracted with EtOAc (100 mL). The combined organic phases were dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by column chromatography (gradient from 30% EtOAc/70% hexane to 100% EtOAc) to give the desired product as an orange oil (0.88 g, 57%): TLC (40% EtOAc/60% hexane) Rf 0.09; 1H-NMR (CDCl3) δ 1.28 (s, 9H), 3.65 (br s, 2H), 5.79 (s, 1H), 7.30 (d, J=6.25 Hz, 2H), 8.47 (d, J=6.25 Hz, 2H); EI-MS m/z (rel abundance) 216 (M, 30%).


A3. Synthesis 3-Amino-5-alkylthiophenes from N—BOC 3-Amino-5-alkyl-2-thiophenecarboxylate esters



embedded image


Step 1. Methyl 3-(tert-Butoxycarbonylamino)-5-tert-butyl-2-thiophenecarboxy-late: To a solution of methyl 3-amino-5-tert-butyl-2-thiophenecarboxylate (150 g, 0.70 mol) in pyridine (2.8 L) at 5° C. was added di-tert-butyl dicarbonate (171.08 g, 0.78 mol, 1.1 equiv) and N,N-dimethylaminopyridine (86 g, 0.70 mol, 1.00 equiv) and the resulting mixture was stirred at room temp for 7 d. The resulting dark solution was concentrated under reduced pressure (approximately 0.4 mmHg) at approximately 20° C. The resulting red solids were dissolved in CH2Cl2 (3 L) and sequentially washed with a 1 M H3PO4 solution (2×750 ml), a saturated NaHCO3 solution (800 mL) and a saturated NaCl solution (2×800 mL), dried (Na2SO4) and concentrated under reduced pressure. The resulting orange solids were dissolved in abs. EtOH (2 L) by warming to 49° C., then treated with water (500 mL) to afford the desired product as an off-white solid (163 g, 74%): 1H-NMR (CDCl3) δ 1.38 (s, 9H), 1.51 (s, 9H), 3.84 (s, 3H), 7.68 (s, 1H), 9.35 (br s, 1H); FAB-MS m/z (rel abundance) 314 ((M+H)+, 45%).




embedded image


Step 2. 3-(tert-Butoxycarbonylamino)-5-tert-butyl-2-thiophenecarboxylic Acid: To a solution of methyl 3-(tert-butoxycarbonylamino)-5-tert-butyl-2-thiophenecarboxylate (90.0 g, 0.287 mol) in THF (630 mL) and MeOH (630 mL) was added a solution of NaOH (42.5 g, 1.06 mL) in water (630 mL). The resulting mixture was heated at 60° C. for 2 h, concentrated to approximately 700 mL under reduced pressure, and cooled to 0° C. The pH was adjusted to approximately 7 with a 1.0 N HCl solution (approximately 1 L) while maintaining the internal temperature at approximately 0° C. The resulting mixture was treated with EtOAc (4 L). The pH was adjusted to approximately 2 with a 1.0 N HCl solution (500 mL). The organic phase was washed with a saturated NaCl solution (4×1.5 L), dried (Na2SO4), and concentrated to approximately 200 mL under reduced pressure. The residue was treated with hexane (1 L) to form a light pink solid (41.6 g). Resubmission of the mother liquor to the concentration-precipitation protocol afforded additional product (38.4 g, 93% total yield): 1H-NMR (CDCl3) δ 1.94 (s, 9H), 1.54 (s, 9H), 7.73 (s, 1H), 9.19 (br s, 1H); FAB-MS m/z (rel abundance) 300 ((M+H)+, 50%).




embedded image


Step 3. 5-tert-Butyl-3-thiopheneammonium Chloride: A solution of 3-(tert-butoxycarbonylamino)-5-tert-butyl-2-thiophenecarboxylic acid (3.0 g, 0.010 mol) in dioxane (20 mL) was treated with an HCl solution (4.0 M in dioxane, 12.5 mL, 0.050 mol, 5.0 equiv), and the resulting mixture was heated at 80° C. for 2 h. The resulting cloudy solution was allowed to cool to room temp forming some precipitate. The slurry was diluted with EtOAc (50 mL) and cooled to −20° C. The resulting solids were collected and dried overnight under reduced pressure to give the desired salt as an off-white solid (1.72 g, 90%): 1H-NMR (DMSO-d6) δ 1.31 (s, 9H), 6.84 (d, J=1.48 Hz, 1H), 7.31 (d, J=1.47 Hz, 1H), 10.27 (br s, 3H).


B. General Methods for Synthesis of Substituted Anilines


B1. General Method for Substituted Aniline Synthesis Via Nucleophilic Aromatic Substitution Using a Halopyridine



embedded image


3-(4-Pyridinylthio)aniline: To a solution of 3-aminothiophenol (3.8 mL, 34 mmoles) in anh DMF (90 mL) was added 4-chloropyridine hydrochloride (5.4 g, 35.6 mmoles) followed by K2CO3 (16.7 g, 121 mmoles). The reaction mixture was stirred at room temp. for 1.5 h, then diluted with EtOAc (100 mL) and water (100 mL). The aqueous layer was back-extracted with EtOAc (2×100 mL). The combined organic layers were washed with a saturated NaCl solution (100 mL), dried (MgSO4), and concentrated under reduced pressure. The residue was filtered through a pad of silica (gradient from 50% EtOAc/50% hexane to 70% EtOAc/30% hexane) and the resulting material was triturated with a Et2O/hexane solution to afford the desired product (4.6 g, 66%): TLC (100% ethyl acetate) Rf 0.29; 1H-NMR (DMSO-d6) δ 5.41 (s, 2H), 6.64-6.74 (m, 3H), 7.01 (d, J=4.8, 2H), 7.14 (t, J=7.8 Hz, 1H), 8.32 (d, J=4.8, 2H).


C. General Methods of Urea Formation


C1a. Reaction of a Heterocyclic Amine with an Aryl Isocyanate




embedded image


N-(1-(4-Methoxyphenyl)-3-tert-butyl-5-pyrazolyl)-N′-(2,3-dichlorophenyl)urea: To a stirring solution of 1-(4-methoxyphenyl)-3-tert-butyl-5-aminopyrazole (0.342 g, 1.39 mmol) in anh toluene (9 mL) was added 2,3-dichlorophenyl isocyanate (0.276 mL, 2.09 mmol). The solution was sealed and stirred in the dark for 96 h at 60° C. After this time, the reaction mixture was diluted with EtOAc (200 mL). The resulting mixture was sequentially washed with a 1 M HCl solution (2×125 mL) and a saturated NaCl solution (50 mL), dried (MgSO4), and concentrated under reduced pressure. The residue was purified by column chromatography (20% EtOAc/80% hexane) to give the product as a white solid (0.335 g, 56%): TLC (20% EtOAc/80% hexane) Rf 0.22; 1H NMR (DMSO-d6) δ 1.24 (s, 9H), 3.79 (s, 3H), 6.33 (s, 1H), 7.05 (d, J=9 Hz, 2H), 7.28 (m, 2H), 7.38 (d, J=9 Hz, 2H), 8.05 (dd, J=3, 6 Hz, 1H), 8.75 (s, 1H), 9.12 (s, 1H); FAB-MS m/z 433 ((M+H)+).


C1b. Reaction of a Heterocyclic Amine with an Aryl Isocyanate




embedded image


N-(2-(4-Pyridinyl)-5-tert-butyl-3-furyl)-N′-(2,3-dichlorophenyl)urea: A solution of 3-amino-2-(4-pyridinyl)-5-tert-butylfuran (Method A2; 0.10 g, 0.46 mmol) and 2,3-dichlorophenyl isocyanate (0.13 g, 0.69 mmol) in CH2Cl2 was stirred at room temp. for 2 h, then was treated with 2-(dimethylamino)ethylamine (0.081 g, 0.92 mmol) and stirred for an additional 30 min. The resulting mixture was diluted with EtOAc (50 mL), then was sequentially washed with a 1 N HCl solution (50 mL), a saturated NaHCO3 solution (50 mL) and a saturated NaCl solution (50 mL), dried (Na2SO4), and concentrated under reduced pressure. The residue was purified using column chromatography (gradient from 10% EtOAc/90% hexane to 40% EtOAc/60% hexane) to give the desired compound as a white solid (0.12 g, 63%): mp 195-198° C.; TLC (60% EtOAc/40% hexane) Rf 0.47; 1H NMR (DMSO-d6) δ1.30 (s, 9H); 6.63 (s, 1H); 7.30-7.32 (m, 2H), 7.58 (dm, J=6.62 Hz, 2H), 8.16 (dd, J=2.57, 6.99 Hz, 1H), 8.60 (dm, J=6.25 Hz, 2H), 8.83 (s, 1H), 9.17 (s, 1H); 13C NMR (DMSO-d6) δ 28.5 (3C), 32.5, 103.7, 117.3 (2C), 119.8, 120.4, 123.7, 125.6, 128.1, 131.6, 135.7, 136.5, 137.9, 150.0 (2C), 152.2, 163.5; CI-MS m/z (rel abundance) 404 ((M+H)+, 15%), 406 ((M+H+2)+, 8%).


C1c. Reaction of a Heterocyclic Amine with an Isocyanate




embedded image


N-(5-tert-Butyl-3-thienyl)-N′-(2,3-dichlorophenyl)urea: Pyridine (0.163 mL, 2.02 mmol) was added to a slurry of 5-tert-butylthiopheneammonium chloride (Method A4c; 0.30 g, 1.56 mmol) and 2,3-dichlorophenyl isocyanate (0.32 mL, 2.02 mmol) in CH2Cl2 (10 mL) to clarify the mixture and the resulting solution was stirred at room temp. overnight. The reaction mixture was then concentrated under reduced pressure and the residue was separated between EtOAc (15 mL) and water (15 mL). The organic layer was sequentially washed with a saturated NaHCO3 solution (15 mL), a 1N HCl solution (15 mL) and a saturated NaCl solution (15 mL), dried (Na2SO4), and concentrated under reduced pressure. A portion of the residue was treated by preparative HPLC (C-18 column; 60% acetonitrile/40% water/0.05% TFA) to give the desired urea (0.180 g, 34%): mp 169-170° C.; TLC (20% EtOAc/80% hexane) Rf 0.57; 1H-NMR (DMSO-d6) δ 1.31 (s, 9H), 6.79 (s, 1H), 7.03 (s, 1H), 7.24-7.33 (m, 2H), 8.16 (dd, J=1.84, 7.72 Hz, 1H), 8.35 (s, 1H), 9.60 (s, 1H); 13C-NMR (DMSO-d6) δ 31.9 (3C), 34.0, 103.4, 116.1, 119.3, 120.0, 123.4, 128.1, 131.6, 135.6, 138.1, 151.7, 155.2; FAB-MS m/z (rel abundance) 343 ((M+H)+, 83%), 345 ((M+H+2)+, 56%), 347 ((M+H+4)+, 12%).


C2. Reaction of Substituted Aniline with N,N′-Carbonyldiimidazole Followed by Reaction with a Heterocyclic Amine



embedded image


N-(1-Phenyl-3-tert-butyl-5-pyrazolyl)-N′-(4-(4-pyridinylmethyl)phenyl)urea: A solution of 4-(4-pyridinylmethyl)aniline (0.25 g, 1.38 mmol) and N,N′-carbonyldiimidazole (0.23 g, 1.42 mmol) in CH2Cl2 11 mL) at room temp. was stirred for 2 h, then treated with 5-amino-1-phenyl-3-tert-butyl-5-pyrazole (0.30 g, 1.38 mmol) and the resulting mixture was stirred at 50° C. overnight. The reaction mixture was diluted with EtOAc (25 mL), then sequentially washed with water (30 mL) and a saturated NaCl solution (30 mL), dried (MgSO4), and concentrated under reduced pressure. The residue was purified by column chromatography (gradient from 100% CH2Cl2 to 30% acetone/70% CH2Cl2) and the resulting material was recrystallized (EtOAc/Et2O) to give the desired product complexed with 0.25 equiv H2O (0.30 g): TLC (60% acetone/40% CH2Cl2) Rf 0.56; 1H-NMR (DMSO-d6) δ 1.25 (s, 9H); 3.86 (s, 2H), 6.34 (s, 1H), 7.11 (d, J=8.82 Hz, 2H), 7.19 (dm, J=6.25 Hz, 2H), 7.31 (d, J=1.84 Hz, 2H), 7.35-7.51 (m, 5H), 8.34 (s, 1H), 8.42 (dm, J=5.98 Hz, 2H), 8.95 (s, 1H); FAB-MS m/z (rel abundance) 426 ((M+H)+, 100%).


D. Interconversion of Ureas


D1. General Method for Electrophylic Halogenation of Aryl Ureas



embedded image


N-(2-Bromo-5-tert-butyl-3-thienyl)-N′-(2-3-dichlorophenyl)urea: To a slurry of N-(5-tert-butyl-3-thienyl)-N′-(2,3-dichlorophenyl)urea (Method C1c; 3.00 g, 8.74 mmol) in CHCl3 (200 mL) at room temp was slowly added a solution of Br2 (0.46 mL, 1.7 mmol) in CHCl3 (150 mL) via addition funnel over 2.5 h, causing the reaction mixture to become homogeneous. Stirring was continued 20 min after which TLC analysis indicated complete reaction. The reaction mixture was concentrated under reduced pressure, and the residue triturated (Et2O/hexane) and the resulting solids were washed (hexane) to give the brominated product as a pink powder (3.45 g, 93%): mp 180-183° C.; TLC (10% EtOAc/90% hexane) Rf 0.68; 1H NMR (DMSO-d6) δ 1.28 (s, 9H), 7.27-7.31 (m, 2H), 7.33 (s, 1H), 8.11 (dd, J=3.3, 6.6 Hz, 1H), 8.95 (s, 1H), 9.12 (s, 1H); 13C NMR (DMSO-d6) δ31.5 (3C), 34.7, 91.1, 117.9, 120.1, 120.5, 123.8, 128.0, 131.6, 135.5, 137.9, 151.6, 155.3; FAB-MS m/z (rel abundance) 421 ((M+H)+, 7%), 423 (M+2+H)+, 10%).


D2. General Method for Metal-Mediated Cross-Coupling Reactions with Halogen-Substituted Ureas



embedded image


N-(2-Phenyl-5-tert-butyl-3-thienyl)-N′-(2,3-dichlorophenyl)urea: To a solution of N-(3-(2-bromo-5-tert-butylthienyl)-N′-(2,3-dichlorophenyl)urea (0.50 g, 1.18 mmol) and phenyltrimethyltin (0.21 mL, 1.18 mmol) in DMF (15 mL) was added Pd(PPh3)2Cl2 (0.082 g, 0.12 mmol), and the resulting suspension was heated at 80° C. overnight. The reaction mixture was diluted with EtOAc (50 mL) and water (50 mL), and the organic layer sequentially washed with water (3×50 mL) and a saturated NaCl solution (50 mL), then dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by MPLC (Biotage®; gradient from 100% hexane to 5% EtOAc/95% hexane) followed by preparative HPLC (C-18 column; 70% CH3CN/30% water/0.05% TFA). The HPLC fractions were concentrated under reduced pressure and the resulting aqueous mixture was extracted with EtOAc (2×50 mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to give a gummy semi-solid, which was triturated with hexane to afford the desired product as a white solid (0.050 g, 10%): mp 171-173° C.; TLC (5% EtOAc/95% hexane) Rf 0.25; 1H NMR (CDCl3) δ1.42 (s, 9H), 6.48 (br s, 1H), 7.01 (s, 1H), 7.10-7.18 (m, 2H), 7.26-7.30 (m, 1H), 7.36 (app t, J=7.72 Hz, 2H), 7.39 (br s, 1H), 7.50 (dm, J=6.99 Hz, 2H), 7.16 (dd, J=2.20, 7.72 Hz, 1H); 13C NMR (CDCl3) δ 32.1 (3C), 34.8, 118.4, 118.8, 120.7, 121.1, 124.2, 127.7, 127.9, 128.2 (2C), 128.5, 129.0 (2C), 132.4, 132.5, 136.9, 153.1, 156.3; FAB-MS m/z (rel abundance) 419 ((M+H)+, 6%), 421 ((M+H+2)+, 4%).


D3. General Methods of Reduction of Nitro-Containing Aryl Ureas



embedded image


N-(1-(3-Aminophenyl)-3-tert-butyl-5-pyrazolyl)-N′-(4-(4-pyridinylthio)phenyl)urea: A solution of N-(1-(3-nitrophenyl)-3-tert-butyl-5-pyrazolyl)-N′-(4-(4-pyridinylthio)phenyl)urea (Prepared in methods analogous to those described in A1 and C1a; 0.310 g, 0.635 mmol) in acetic acid (20 mL) was placed under an atmosphere of Ar using a vacuum-degassed and argon-purge protocol. To this was added water (0.2 mL) followed by iron powder (325 mesh; 0.354 g, 6.35 mmol). The reaction mixture was stirred vigorously under argon at room temp. for 18 h, at which time TLC indicated the absence of starting material. The reaction mixture was filtered and the solids were washed copiously with water (300 mL). The orange solution was then brought to pH 4.5 by addition of NaOH pellets (a white precipitate forms). The resulting suspension was extracted with Et2O (3×250 mL), and the combined organic layers were washed with a saturated NaHCO3 solution (2×300 mL) until foaming ceased. The resulting solution was dried (MgSO4) and concentrated under reduced pressure. The resulting white solid was purified by column chromatography (gradient from 30% acetone/70% CH2Cl2 to 50% acetone/50% CH2Cl2) to give the product as a white solid (0.165 g, 57%): TLC (50% acetone/50% CH2Cl2) Rf 0.50; 1H NMR (DMSO-d6) δ 1.24 (s, 9H), 5.40 (br s, 2H), 6.34 (s, 1H), 6.57 (d, J=8 Hz, 2H), 6.67 (s, 1H), 6.94 (d, J=6 Hz, 2H), 7.12 (app t, J=8 Hz, 1H), 7.47 (d, J=9 Hz, 2H), 7.57 (d, J=9 Hz, 2H), 8.31 (d, J=6 Hz, 2H), 8.43 (s, 1H), 9.39 (s, 1H); FAB-MS m/z 459 ((M+H)+).


D4. General Methods of Acylation of Amine-Containing Aryl Ureas



embedded image


N-(1-(3-Acetamidophenyl)-3-tert-butyl-5-pyrazolyl)-N′-(4-phenoxyphenyl)urea: To a solution of N-(1-(3-aminophenyl)-3-tert-butyl-5-pyrazolyl)-N′-(4-phenoxyphenyl)urea (prepared using methods analogous to those described in A1, C1a and D3; 0.154 g, 0.349 mmol) in CH2Cl2 (10 mL) was added pyridine (0.05 mL) followed by acetyl chloride (0.030 mL, 0.417 mmol). The reaction mixture was stirred under argon at room temp. for 3 h, at which time TLC analysis indicated the absence of starting material. The reaction mixture was diluted with CH2Cl2(20 mL), then the resulting solution was sequentially washed with water (30 mL) and a saturated NaCl solution (30 mL), dried (MgSO4) and concentrated under reduced pressure. The resulting residue was purified by column chromatography (gradient from 5% EtOAc/95% hexane to 75% EtOAc/25% hexane) to give the product as a white solid (0.049 g, 30%): TLC (70% EtOAc/30% hexane) Rf 0.32; 1H NMR (DMSO-d6) δ 1.26 (s, 9H), 2.05 (s, 3H), 6.35 (s, 1H), 6.92-6.97 (m, 4H), 7.05-7.18 (m, 2H), 7.32-7.45 (m, 5H), 7.64-7.73 (m, 2H), 8.38 (s, 1H), 9.00 (s, 1H), 10.16 (s, 1H); FAB-MS m/z 484 ((M+H)+).


The following compounds have been synthesized according to the General Methods listed above:









TABLE 1







2-Substituted-5-tert-butylpyrazolyl Ureas




embedded image

























Mass






mp
TLC
Solvent
Spec.
Synth.


Entry
R1
R2
(° C.)
Rf
System
[Source]
Method

















1


embedded image




embedded image



0.42
20%EtOAc/80%hexane
403(M + H)+[FAB]
A1,C1a





2


embedded image




embedded image



0.50
67%EtOAc/33%hexane
418(M + H)+[FAB]
A1,C1a,D3





3


embedded image




embedded image



0.27
20%EtOAc/80%hexane
417(M + H)+[FAB]
A1,C1a





4


embedded image




embedded image



0.47
20%EtOAc/80%hexane
404(M + H)+[FAB]
A1,C1a





5


embedded image




embedded image



0.30
33%EtOAc/67%hexane
473(M + H)+[FAB]
A1,C1a





6


embedded image




embedded image



0.27
100%EtOAc
421(M + H)+[FAB]
A1,C1a





7


embedded image




embedded image



0.50
20%EtOAc/80%hexane
437(M + H)+[FAB]
A1,C1a





8


embedded image




embedded image



0.60
50%EtOAc/50%hexane
481(M + H)+[FAB]
A1,C1a





9


embedded image




embedded image



0.37
20%EtOAc/80%hexane
448(M + H)+[FAB]
A1,C1a





10


embedded image




embedded image



0.35
20%EtOAc/80%hexane
433(M + H)+[FAB]
A1,C1a





11


embedded image




embedded image



0.40
20%EtOAc/80%hexane
471(M + H)+[FAB]
A1,C1a





12


embedded image




embedded image



0.22
20%EtOAc/80%hexane
433(M + H)+[FAB]
A1,C1a





13


embedded image




embedded image



0.51
20%EtOAc/80%hexane
445(M + H)+[FAB]
A1,C1a





14


embedded image




embedded image



0.39
50%EtOAc/50%hexane
418(M + H)+[FAB]
A1,C1a,D3





15


embedded image




embedded image



0.31
30%EtOAc/70%hexane
448(M + H)+[FAB]
A1,C1a





16


embedded image




embedded image


195-200


437(M + H)+[FAB]
A1,C1a





17


embedded image




embedded image


97-100


403(M + H)+[FAB]
A1,C1a





18


embedded image




embedded image


84-85


371(M + H)+[FAB]
A1,C1a





19


embedded image




embedded image


156-159


353(M + H)+[FAB]
A1,C1a





20


embedded image




embedded image


168-169


360(M + H)+[FAB]
A1,C1a





21


embedded image




embedded image


131-135


380(M + H)+[CI]
A1,C1a





22


embedded image




embedded image



0.31
70%EtOAc/30%hexane
484(M + H)+[FAB]
A1,C1a,D3, D4





23


embedded image




embedded image



0.14
50%EtOAc/50%hexane
442(M + H)+[FAB]
A1,C1a,D3





24


embedded image




embedded image



0.19
30%EtOAc/70%hexane
472(M + H)+[FAB]
A1,C1a





25


embedded image




embedded image



0.56
60%acetone/40%CH2Cl2
426(M + H)+[FAB]
A1, C2





26


embedded image




embedded image



0.34
10%MeOH/90%CH2Cl2
427(M + H)+[FAB]
A1, C2





27


embedded image




embedded image



0.44
40%acetone/60%CH2Cl2
494(M + H)+[FAB]
A1, C2





28


embedded image




embedded image



0.44
40%acetone/60%CH2Cl2
444(M + H)+[FAB]
A1, C2





29


embedded image




embedded image



0.46
40%acetone/60%CH2Cl2
440(M + H)+[FAB]
A1, C2





30


embedded image




embedded image



0.48
40%acetone/60%CH2Cl2
444(M + H)+[FAB]
A1, C2





31


embedded image




embedded image



0.34
40%acetone/60%CH2Cl2
504(M + H)+
A1, C2





32


embedded image




embedded image



0.47
40%acetone/60%CH2Cl2
471(M + H)+[FAB]
A1, C2





33


embedded image




embedded image



0.51
60%acetone/40%CH2Cl2
456(M + H)+[FAB]
A1, C2





34


embedded image




embedded image



0.50
50%acetone/50%CH2Cl2
441(M + H)+[FAB]
A1, C2,D3





35


embedded image




embedded image



0.43
30%acetone/70%CH2Cl2
471(M + H)+[FAB]
A1, C2





36


embedded image




embedded image



0.50
50%acetone/50%CH2Cl2
459(M + H)+[FAB]
A1, C2,D3





37


embedded image




embedded image



0.47
30%acetone/70%CH2Cl2
489(M + H)+[FAB]
A1, C2





38


embedded image




embedded image



0.47
50%EtOAc/50%hexane
620(M + H)+[FAB]
A1, C2





39


embedded image




embedded image



0.34
50%EtOAc/50%hexane
433(M + H)+[FAB]
A1, C2
















TABLE 2







Additional Ureas















mp
TLC
Solvent
Mass
Synth.


Entry
R2
(° C.)
Rf
System
Spec.
Method





40


embedded image


195-198
0.47
60%EtOAc/40%hexane
404(M + H)+[FAB]
A2,C1b





41


embedded image


171-173
0.25
5%EtOAc/95%hexane
419(M + H)+[FAB]
A3,C1c,D1, D2









BIOLOGICAL EXAMPLES

In Vitro raf Kinase Assay:


In an in vitro kinase assay, raf is incubated with MEK in 20 mM Tris-HCl, pH 8.2 containing 2 mM 2-mercaptoethanol and 100 mM NaCl. This protein solution (20 μL) is mixed with water (5 μL) or with compounds diluted with distilled water from 10 mM stock solutions of compounds dissolved in DMSO. The kinase reaction is initiated by adding 25 μL [γ-33P]ATP (1000-3000 dpm/pmol) in 80 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1.6 mM DTT, 16 mM MgCl2. The reaction mixtures are incubated at 32° C., usually for 22 min. Incorporation of 33P into protein is assayed by harvesting the reaction onto phosphocellulose mats, washing away free counts with a 1% phosphoric acid solution and quantitating phosphorylation by liquid scintillation counting. For high throughput screening, 10 μM ATP and 0.4 μM MEK are used. In some experiments, the kinase reaction is stopped by adding an equal amount of Laemmli sample buffer. Samples are boiled 3 min and the proteins resolved by electrophoresis on 7.5% Laemmli gels. Gels are fixed, dried and exposed to an imaging plate (Fuji). Phosphorylation is analyzed using a Fujix Bio-Imaging Analyzer System.


All compounds exemplified displayed IC50s of between 10 nM and 10 μM.


Cellular Assay:


For in vitro growth assay, human tumor cell lines, including but not limited to HCT116 and DLD-1, containing mutated K-ras genes are used in standard proliferation assays for anchorage dependent growth on plastic or anchorage independent growth in soft agar. Human tumor cell lines were obtained from ATCC (Rockville Md.) and maintained in RPMI with 10% heat inactivated fetal bovine serum and 200 mM glutamine. Cell culture media and additives are obtained from Gibco/BRL (Gaithersburg, Md.) except for fetal bovine serum (JRH Biosciences, Lenexa, Kans.). In a standard proliferation assay for anchorage dependent growth, 3×103 cells are seeded into 96-well tissue culture plates and allowed to attach overnight at 37° C. in a 5% CO2 incubator. Compounds are titrated in media in dilution series and added to 96 well cell cultures. Cells are allowed to grow 5 days typically with a feeding of fresh compound containing media on day three. Proliferation is monitored by measuring metabolic activity with standard XTT colorimetric assay (Boehringer Mannheim) measured by standard ELISA plate reader at OD 490/560, or by measuring 3H-thymidine incorporation into DNA following an 8 h culture with 1 μCu 3H-thymidine, harvesting the cells onto glass fiber mats using a cell harvester and measuring 3H-thymidine incorporation by liquid scintillant counting.


For anchorage independent cell growth, cells are plated at 1×103 to 3×103 in 0.4% Seaplaque agarose in RPMI complete media, overlaying a bottom layer containing only 0.64% agar in RPMI complete media in 24-well tissue culture plates. Complete media plus dilution series of compounds are added to wells and incubated at 37° C. in a 5% CO2 incubator for 10-14 days with repeated feedings of fresh media containing compound at 3-4 day intervals. Colony formation is monitored and total cell mass, average colony size and number of colonies are quantitated using image capture technology and image analysis software (Image Pro Plus, media Cybernetics).


These assays establish that the compounds of formula I are active to inhibit raf kinase activity and to inhibit oncogenic cell growth.


In Vivo Assay:


An in vivo assay of the inhibitory effect of the compounds on tumors (e.g., solid cancers) mediated by raf kinase can be performed as follows:


CDI nu/nu mice (6-8 weeks old) are injected subcutaneously into the flank at 1×106 cells with human colon adenocarcinoma cell line. The mice are dosed i.p., i.v. or p.o. at 10, 30, 100, or 300 mg/Kg beginning on approximately day 10, when tumor size is between 50-100 mg. Animals are dosed for 14 consecutive days once a day; tumor size was monitored with calipers twice a week.


The inhibitory effect of the compounds on raf kinase and therefore on tumors (e.g., solid cancers) mediated by raf kinase can further be demonstrated in vivo according to the technique of Monia et al. (Nat. Med. 1996, 2, 668-75).


The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.


From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims
  • 1. A compound of formula I or a pharmaceutically acceptable salt thereof
  • 2. A compound of claim 1, wherein R1 is t-butyl and R2 is unsubstituted or substituted phenyl.
  • 3. A compound of claim 1 of the formula
  • 4. A compound of claim 1 wherein one of the following combinations is satisfied: R2=unsubstituted phenyl, B=phenyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=unsubstituted phenyl, B=pyridinyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=unsubstituted phenyl, B=naphthyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=unsubstituted pyridinyl, B=phenyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=unsubstituted pyridinyl, B=pyridinyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=unsubstituted pyridinyl, B=naphthyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=substituted phenyl, B=phenyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=substituted phenyl, B=pyridinyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=substituted phenyl, B=naphthyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=substituted pyridinyl, B=phenyl and L1 is pyridinyl, quinolinyl or isoquinolinyl,R2=substituted pyridinyl, B=pyridinyl and L1 is pyridinyl, quinolinyl or isoquinolinyl, orR2=substituted pyridinyl, B=naphthyl and L1 is pyridinyl, quinolinyl isoquinolinyl.
  • 5. A compound of Formula I or a pharmaceutically acceptable salt thereof
  • 6. A compound as in claim 5 wherein B is optionally substituted pyridinyloxyphenyl, benzothiazolyloxyphenyl, benzothiazolylthiophenyl, pyrimidinyloxyphenyl, quinolinylthiophenyl, and phthalimidylmethylphenyl and R2 is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl.
  • 7. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
Parent Case Info

This application is a continuation of Ser. No. 09/303,621 filed Dec. 22, 1998 now abandoned which claims priority of provisional application 60/135,502 filed Dec. 22, 1997.

US Referenced Citations (115)
Number Name Date Kind
2046375 Goldstein et al. Jul 1936 A
2093265 Coffby et al. Sep 1937 A
2288422 Rohm Jun 1942 A
2649476 Martin Aug 1953 A
2683082 Hill et al. Jul 1954 A
2722544 Martin Nov 1955 A
2745874 Schetty et al. May 1956 A
2781330 Downey Feb 1957 A
2797214 Bossard Jun 1957 A
2867659 Model et al. Jan 1959 A
2877268 Applegate et al. Mar 1959 A
2960488 Tamblyn et al. Nov 1960 A
2973386 Weldon Feb 1961 A
3151023 Martin Sep 1964 A
3200035 Martin et al. Aug 1965 A
3230141 Frick et al. Jan 1966 A
3424760 Helsley et al. Jan 1969 A
3424761 Helsley et al. Jan 1969 A
3424762 Helsley et al. Jan 1969 A
3547940 Brantley Dec 1970 A
3646059 Brantley Feb 1972 A
3689550 Schellenbaum et al. Sep 1972 A
3743498 Brantley Jul 1973 A
3754887 Brantley Aug 1973 A
3823161 Lesser Jul 1974 A
3828001 Broad et al. Aug 1974 A
3860645 Nikawitz Jan 1975 A
3990879 Soper Nov 1976 A
4001256 Callahan et al. Jan 1977 A
4009847 Aldrich et al. Mar 1977 A
4042372 Harper Aug 1977 A
4062861 Yukinaga et al. Dec 1977 A
4071524 Banitt Jan 1978 A
4111680 Yukinaga et al. Sep 1978 A
4111683 Singer Sep 1978 A
4116671 Yukinaga et al. Sep 1978 A
4173637 Nishiyama et al. Nov 1979 A
4173638 Nishiyama et al. Nov 1979 A
4183854 Crossley Jan 1980 A
4212981 Yukinaga et al. Jul 1980 A
4240820 Dickore et al. Dec 1980 A
4279639 Okamoto et al. Jul 1981 A
4405644 Kabbe et al. Sep 1983 A
4410697 Török et al. Oct 1983 A
4437878 Acker et al. Mar 1984 A
4468380 O'Doherty et al. Aug 1984 A
4473579 Devries et al. Sep 1984 A
4511571 Böger et al. Apr 1985 A
4514571 Nakai et al. Apr 1985 A
4526997 O'Doherty et al. Jul 1985 A
4623662 De Vries Nov 1986 A
4643849 Hirai et al. Feb 1987 A
4740520 Hallenbach et al. Apr 1988 A
4760063 Hallenbach et al. Jul 1988 A
4808588 King Feb 1989 A
4820871 Kissener et al. Apr 1989 A
4863924 Haga et al. Sep 1989 A
4973675 Israel et al. Nov 1990 A
4983605 Kondo et al. Jan 1991 A
4985449 Haga et al. Jan 1991 A
5036072 Nakajima et al. Jul 1991 A
5059614 Lepage et al. Oct 1991 A
5098907 Kondo et al. Mar 1992 A
5130331 Pascual Jul 1992 A
5162360 Creswell et al. Nov 1992 A
5185358 Creswell Feb 1993 A
5312820 Ashton et al. May 1994 A
5319099 Kamata et al. Jun 1994 A
5399566 Katano et al. Mar 1995 A
5423905 Fringeli Jun 1995 A
5429918 Seto et al. Jul 1995 A
5447957 Adams et al. Sep 1995 A
5470882 Dixon et al. Nov 1995 A
5500424 Nagamine et al. Mar 1996 A
5508288 Forbes et al. Apr 1996 A
5596001 Hamanaka Jan 1997 A
5597719 Freed et al. Jan 1997 A
5696138 Olesen et al. Dec 1997 A
5698581 Kleemann et al. Dec 1997 A
5773459 Tang et al. Jun 1998 A
5780483 Widdowson et al. Jul 1998 A
5807891 Bold et al. Sep 1998 A
5814646 Heinz Sep 1998 A
5886044 Widdowson et al. Mar 1999 A
5891895 Shiraishi et al. Apr 1999 A
5908865 Doi et al. Jun 1999 A
5929250 Widdowson et al. Jul 1999 A
5965573 Petrie et al. Oct 1999 A
6004965 Breu et al. Dec 1999 A
6005008 Widdowson et al. Dec 1999 A
6015908 Widdowson et al. Jan 2000 A
6020345 Vacher et al. Feb 2000 A
6022884 Mantlo et al. Feb 2000 A
6043374 Widdowson et al. Mar 2000 A
6080763 Regan et al. Jun 2000 A
6093742 Salituro et al. Jul 2000 A
6133319 Widdowson Oct 2000 A
6143764 Kubo et al. Nov 2000 A
6147116 Barbachyn et al. Nov 2000 A
6174901 Mantlo et al. Jan 2001 B1
6180675 Widdowson et al. Jan 2001 B1
6211373 Widdowson et al. Apr 2001 B1
6218539 Widdowson Apr 2001 B1
6242601 Breu et al. Jun 2001 B1
6262113 Widdowson et al. Jul 2001 B1
6271261 Widdowson Aug 2001 B1
6319921 Cirillo et al. Nov 2001 B1
6333341 Mantlo et al. Dec 2001 B1
6339045 Kanno et al. Jan 2002 B1
6344476 Ranges et al. Feb 2002 B1
6391917 Petrie et al. May 2002 B1
20020062763 Macholdt et al. May 2002 A1
20020065296 Dumas et al. May 2002 A1
20020082255 Eastwood Jun 2002 A1
20020128321 Widdowson et al. Sep 2002 A1
Foreign Referenced Citations (109)
Number Date Country
2146707 Oct 1995 CA
0 487 014 Dec 1929 DE
0 511 468 Oct 1930 DE
0 523 437 May 1931 DE
2436179 Feb 1975 DE
25 01 648 Jul 1975 DE
3305866 Feb 1983 DE
35 29 247 Aug 1985 DE
35 40 377 Nov 1985 DE
0 253 997 Feb 1988 DE
3540377 Jul 1988 DE
16371 Mar 1980 EP
0107214 May 1984 EP
0116932 Aug 1984 EP
0192263 Aug 1986 EP
0230400 Jul 1987 EP
0233559 Aug 1987 EP
242666 Oct 1987 EP
0264904 Apr 1988 EP
335156 Mar 1989 EP
371876 Nov 1989 EP
0359148 Mar 1990 EP
0379915 Aug 1990 EP
0380048 Aug 1990 EP
0381987 Aug 1990 EP
425443 Oct 1990 EP
0 405 233 Jan 1991 EP
04085233 Jan 1991 EP
459887 May 1991 EP
0 502 504 Sep 1992 EP
676395 Jul 1996 EP
860433 Aug 1998 EP
0860433 Aug 1998 EP
1 457 172 Sep 1966 FR
0 828 231 Oct 1956 GB
0 771 333 Mar 1957 GB
0 921 682 Mar 1963 GB
1590870 Jun 1981 GB
26555 Jan 2000 IR
44 2569 Feb 1969 JP
50-76072 Jun 1975 JP
50-149668 Nov 1975 JP
51 063170 Jun 1976 JP
51-80862 Jul 1976 JP
53 086033 Jul 1978 JP
54-032468 Sep 1979 JP
55 98152 Jul 1980 JP
50-77375 Sep 1980 JP
55-124763 Sep 1980 JP
55-162772 Dec 1980 JP
3 532 47 Mar 1991 JP
8 301841 Nov 1996 JP
10-306078 Nov 1998 JP
6124 Jan 2000 LB
9602112 Mar 1990 WO
9318028 Sep 1993 WO
9324458 Dec 1993 WO
9414801 Jul 1994 WO
9418170 Aug 1994 WO
94 22807 Oct 1994 WO
9425012 Nov 1994 WO
9502591 Jan 1995 WO
9507922 Mar 1995 WO
9513067 May 1995 WO
9531451 Nov 1995 WO
9533458 Dec 1995 WO
WO 9610559 Apr 1996 WO
WO 9613632 May 1996 WO
9625157 Aug 1996 WO
9640673 Dec 1996 WO
A1 9640675 Dec 1996 WO
9729743 Aug 1997 WO
9730992 Aug 1997 WO
9740028 Oct 1997 WO
9745400 Dec 1997 WO
9749399 Dec 1997 WO
9749400 Dec 1997 WO
WO 9817267 Apr 1998 WO
9822103 May 1998 WO
9822432 May 1998 WO
9717329 Aug 1998 WO
9852559 Nov 1998 WO
WO 9852558 Nov 1998 WO
WO 9852559 Nov 1998 WO
WO 9933458 Nov 1998 WO
9900357 Jan 1999 WO
9900370 Jan 1999 WO
WO 9920617 Apr 1999 WO
WO 9932110 Apr 1999 WO
9923091 May 1999 WO
9924398 May 1999 WO
WO 9921835 May 1999 WO
WO 9924635 May 1999 WO
9932111 Jul 1999 WO
9932437 Jul 1999 WO
9932455 Jul 1999 WO
WO 9932106 Jul 1999 WO
WO 9932436 Jul 1999 WO
WO 9932463 Jul 1999 WO
0017175 Sep 1999 WO
0043384 Jul 2000 WO
WO 0041698 Jul 2000 WO
WO 0042012 Jul 2000 WO
WO 0043366 Jul 2000 WO
WO 0047577 Aug 2000 WO
0055139 Sep 2000 WO
0055152 Sep 2000 WO
WO 0136403 May 2001 WO
WO 0224635 Mar 2002 WO
Provisional Applications (1)
Number Date Country
60135502 Dec 1997 US
Continuations (1)
Number Date Country
Parent 09303621 Dec 1998 US
Child 09472232 US